Canada markets close in 1 hour 21 minutes

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.71-0.25 (-4.19%)
As of 02:39PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close5.96
Open5.96
Bid5.68 x 1200
Ask5.69 x 1300
Day's Range5.65 - 5.96
52 Week Range5.64 - 17.25
Volume3,661,675
Avg. Volume4,774,504
Market Cap1.749B
Beta (5Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-1.25
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.67
  • GlobeNewswire

    Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference

    SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: Evercore ISI 4th Annual HealthCONx ConferenceWednesday, December 1, 2021 at 3:30-3:50 PM EST (Track 3)Registration link: 4th Annual Evercore ISI HealthCONx Conference (wsw.com) An updated corporate presentation will be available at www.sorrentotherapeutics.com. About Sorrento Therapeutics,

  • GlobeNewswire

    Sorrento Publishes an Abivertinib Teaser Entitled “Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases”

    Key Abivertinib Programs Key Abivertinib Programs SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced the publication of a Teaser titled “Abivertinib – a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases” (“Abivertinib Teaser”). Sorrento intends to use the Abivertinib Teaser to engage in discussions with interested third parties in the pharmaceutical industry. The key highlights of the Abivertinib Teaser are ou

  • GlobeNewswire

    Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market

    SAN DIEGO and MEXICO CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with a leading local distributor for the sale and distribution of up to 5 million COVI-STIX™ tests for the Mexican market. Since its commercial launch in July, the COVI-STIX COVID-19 Virus Rapid Antigen Detection Test has been well received for its ease of use and rapid generation of results. In a